XenoPort Inc: Premium Company Profile

Publication Date	December 2007
Publisher	Datamonitor
Product Type	Databook
Pages	47
ISBN Number	not applicable
Product Code	DAT09428

Price

£265.00
approximately: $521 | €337

PRINT £265 ($521 | €337)

Order above formats by FAX

Summary

Introduction

XenoPort is a biopharmaceutical company with therapeutic focus in the areas of central nervous system (CNS) and gastrointestinal tract (GI). Its product pipeline is based on its proprietary Transported Prodrug technology platform, which is focused on improving upon the pharmacologic properties of currently available therapeutics.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

XenoPort's pipeline includes XP19986, indicated for gastro-esophageal reflux disease (Phase IIa) and spasticity (Phase I), and XP13512 indicated for Restless Legs Syndrome (Phase III) and neuropathic pain (Phase IIa).

The key elements ofit's business strategy include: entering into strategic alliances with other pharmaceutical/biotechnology companies for discovery, development and commercialization of its product candidates; advancing clinical development of its product candidates; and Transported Prodrug to discover new product candidates.

The company's total revenues increased at a CAGR of 99.2% during 2002-2006, from $0.7 million to $10.6 million. The company's only contributor to revenue growth during 2002-2006 was revenues from license, collaboration and others.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Products & Services
- Pipeline Products
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
Overview
- Product Development
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: XenoPort - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: XenoPort - Key Strategic Revenues, 2006-2010 ($ Mn)
- Table 1: XenoPort - Key Facts
- Table 2: XenoPort - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 3: XenoPort - Key Events Impacting Share Price Performance
- Table 4: XenoPort - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 5: XenoPort - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 6: XenoPort - Balance Sheet, 2002-2006 ($ Mn)
- Table 7: XenoPort - Cash Flow, 2002-2006 ($ Mn)
- Table 8: XenoPort - Revenue Breakdown by Division, 2002-2006 ($ Mn)
- Table 9: XenoPort - in-house Pipeline Products
- Table 10: XenoPort - Collaboration Products
- Table 11: XenoPort - Forecast Sales, 2006-2010 ($ Mn)
- Table 12: XenoPort - Key Competitors
- Table 13: XenoPort - Key Clients
- Table 14: XenoPort - Key Shareholders
- Table 15: XenoPort - SWOT Analysis Summary
- Table 16: XenoPort - Value Chain Analysis
- Table 17: XenoPort - Scorecard
- Table 18: XenoPort - Key Employees
- Table 19: XenoPort - Financial and Operational Overview